
Adipogen/Regorafenib/AG-CR1-3623-M025/25 mg
商品编号:
AG-CR1-3623-M025
品牌:
Adipogen Inc
市场价:
¥1200.00
美元价:
720.00
产品分类:
其他试剂
公司分类:
Other_reagents
联系Q Q:
3392242852
电话号码:
4000-520-616
电子邮箱:
info@ebiomall.com
商品介绍
Product Details | |
---|---|
Synonyms | BAY 73-4506; Fluoro-Sorafenib |
Product Type | Chemical |
Properties | |
Formula | C21H15ClF4N4O3 |
MW | 482.8 |
CAS | 755037-03-7 |
Purity Chemicals | ≥98% (HPLC) |
Appearance | Light pink to white solid. |
Solubility | Soluble in DMSO (>50mg/ml). Slightly soluble in ethanol (1mg/ml). Insoluble in water. |
InChi Key | FNHKPVJBJVTLMP-UHFFFAOYSA-N |
Shipping and Handling | |
Shipping | AMBIENT |
Short Term Storage | +4°C |
Long Term Storage | -20°C |
Handling Advice |
Keep cool and dry. Protect from light. |
Use/Stability | Stable for at least 2 years after receipt when stored at -20°C. |
Documents | |
MSDS |
![]() |
Product Specification Sheet | |
Datasheet |
![]() |
- Orally bioavailable potent antitumor, antiangiogenic, antiproliferative and antineoplastic agent.
- Multi-target kinase inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ, Kit, RET and Raf-1 with IC50 values of 13, 4.2, 46, 22, 7, 1.5 and 2.5nM, respectively.
Product References
- Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity: S.M. Wilhelm, et al.; Int. J. Cancer 129, 245 (2011)
- Differential properties of current tyrosine kinase inhibitors in gastrointestinal stromal tumors: G.D. Demetri; Semin. Oncol. 38, S10 (2011)
- Regorafenib: a guide to its use in advanced gastrointestinal stromal tumor (GIST) after failure of imatinib and sunitinib: K.A. Lyseng-Williamson, et al.; BioDrugs 27, 525 (2013) (Review)
- Regorafenib: a novel multitargeted tyrosine kinase inhibitor for colorectal cancer and gastrointestinal stromal tumors: D.J. Crona, et al.; Ann. Pharmacother. 47, 1685 (2013) (Review)
- Regorafenib (BAY 73-4506): antitumor and antimetastatic activities in preclinical models of colorectal cancer: R. Schmieder, et al.; Int. J. Cancer 135, 1487 (2014)
- Regorafenib impairs mitochondrial functions, activates AMP-activated protein kinase, induces autophagy, and causes rat hepatocyte necrosis: Z. Weng, et al.; Toxicology 327, 10 (2015)
品牌介绍
Adipogen公司由三个子公司组成,分别是Adipogen,Inc.(韩国),AdipogenSA(瑞士)和 AdipogenCorporation(美国圣地亚哥)。总部设在美国,运营总部在瑞士利斯塔尔。Adipogen公司专门从事生命科学研究试剂的开发,如癌症、免疫、炎症、代谢疾病(糖尿病、肥胖)、干细胞和神经退行性疾病等领域。其重点关注开发创新优质的ELISA试剂盒。另外,也可提供抗体和蛋白产品,Adipogen拥有自己的化学实验室,致力于开发创新型小分子化合物。
联络我们